GGrantIndex
Sort

30,917 grants matching tumor microenvironment

Early phase clinical trial for imaging tumor acidosis in breast cancer patients using acidoCEST MRI

$351,036
Julio Cardenas-Rodriguez · University Of Arizona · R01 · FY2016 · CA

Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation

$351,030
Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2023 · CA

Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation

$351,029
Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2022 · CA

Role of ER-membrane contacts in biogenesis of RNA-containing EVs

$351,002
Alissa M Weaver · Vanderbilt University · P01 · FY2021 · CA

Drivers of metabolic plasticity promote radiation resistance in glioblastoma multiforme

$351,000
Erina Vlashi · University Of California Los Angeles · R01 · FY2023 · CA

Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery

$350,990
Marxa L. Figueiredo · Purdue University · R01 · FY2019 · CA

The Role of Egfl6 in Tumor Immunity

$350,974
Sandra Cascio · Magee-Women'S Res Inst And Foundation · R01 · FY2023 · CA

Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics

$350,957
Ruben D Carrasco · Dana-Farber Cancer Inst · R01 · FY2010 · CA

Replication stress response defects predict and enhance immune checkpoint therapy response in triple negative breast cancer

$350,935
Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Aim/Project 1. Dose-response at single-cell and population levels

$350,854
Peter Karl Sorger · Harvard Medical School · P50 · FY2018 · GM

Engineering S. typhimurium for metastatic colorectal cancer

$350,841
Tal Danino · Columbia Univ New York Morningside · R01 · FY2022 · EB

Metabolic Reprogramming of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy

$350,834
Udai S Kammula · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

Metabolic Reprogramming of Tumor Infiltrating Lymphocytes for Adoptive Immunotherapy

$350,834
Udai S Kammula · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA

CXCL5/CXCR2 axis as a therapeutic vulnerability of breast cancer metastasis to bone

$350,834
Laurie E Littlepage · University Of Notre Dame · R01 · FY2022 · CA

Targeting TIGIT and PD-1 in Melanoma

$350,834
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

Role of ICAM1 in development and progression of pancreatic cancer

$350,834
Peter Storz · Mayo Clinic Jacksonville · R01 · FY2023 · CA

Role of ICAM1 in development and progression of pancreatic cancer

$350,834
Peter Storz · Mayo Clinic Jacksonville · R01 · FY2022 · CA

Extracellular vesicle RNA signaling in liver tumor microenvironment

$350,834
Tushar Patel · Mayo Clinic Jacksonville · R01 · FY2022 · CA

CXCL5/CXCR2 axis as a therapeutic vulnerability of breast cancer metastasis to bone

$350,834
Laurie E Littlepage · University Of Notre Dame · R01 · FY2023 · CA

Mechanisms Controlling Cellular Differentiation and Proliferation in a Plant Stem Cell Microenvironment

$350,820
Naden Krogan · American University · R15 · FY2015 · GM

Computational model of targeted drug delivery

$350,791
Dieter Haemmerich · Medical University Of South Carolina · R01 · FY2023 · CA

Project 4: Thymic and peripheral Aspects of T cell Aging and Rejuvenation

$350,753
Janko Nikolich-Zugich · University Of Arizona · P01 · FY2021 · AG

Leveraging biological insights to enhance immunotherapies

$350,734
Robbie G. Majzner · Children'S Hosp Of Philadelphia · P01 · FY2024 · CA

Core C: CODEX Core

$350,708
Garry P Nolan · Stanford University · P01 · FY2021 · CA

Project 3: Increasing the potency and accessibility of EBVSTs for the treatment of Lymphoma

$350,699
Cliona M Rooney · Baylor College Of Medicine · P50 · FY2023 · CA